AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03098511 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neurological Diagnostic Evaluation
Description: Clinical Data:~* Demographic data~* Daily data (clinical exams, laboratory data)~* Drug administration~* Additional clinical or ancillary neurological determination test~Diagnostic Intervention:~* CT-Perfusion~* CT-Angiography reconstructions~Reference Standard:~- Clinical Neurological Exam~Blood Samples (Pharmacokinetics, Inflammatory \& Nanovesicles Parameters):~* At the time of patient enrolment~* 6 hours after patient enrolment~* At the time of the clinical neurological exam~Secondary Outcome measures at 6 months:~* extended Glasgow Outcome Scale (GOSe)~* modified Rankin Scale (mRS)
Study NCT02754258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 days on oral placebo administered 2 times daily before lunch and supper
Study NCT03833466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin and chemotherapy
Description: Drug: Metformin Metformin is orally administered as 500mg bid for 7 days and escaladed to 500mg tid if adverse events are tolerated.~Drug: Cisplatin Cisplatin is given at 75mg/m2 intravenously on day 1 of each 21 day cycle.~Drug: Paclitaxel Paclitaxel is given at 175mg/m2 intravenously on day 1 of each 21 day cycle.
Study NCT02567565 — intervention group
Intervention type: OTHER
Intervention: LipiView
Description: tear film lipid layer thickness measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
Study NCT00510744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pancreatic enzyme supplement
Description: 4 caps with meals, 2 with snacks
Study NCT01719133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: saline solution
Study NCT01910818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment
Description: Patient will be treated with fractional laser treatment over the areas with fibrosis.
Study NCT01910818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment
Description: Patient will also have an area that is not being treated with CO2 laser. This is the area not getting treatment.
Study NCT00524420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: 10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions at 120% motor threshold rTMS to left dorsolateral prefrontal cortex
Study NCT00524420 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: 10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions of sham rTMS
Study NCT03474874 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NeoMatriX Collagen Dressing
Description: Collagen wound dressing
Study NCT03498456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan/Amoxicillin/Clarithromycin
Description: Tegoprazan 50 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
Study NCT03498456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole/Amoxicillin/Clarithromycin
Description: Lansoprazole 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
Study NCT01697982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living with Hope Program
Description: The Living with Hope Program involves viewing a short film entitled Living with Hope, which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope. Participants then choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection.
Study NCT01697982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LWH film
Description: Participants will view the Living with Hope film which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope.
Study NCT02169089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Patients will be given Spironolactone 12.5 mg on week 0 (visit 2). Patients will be escalated to 25 mg daily Spironolactone or maximal tolerated dose over a 4-week period. Patients will continue treatment for an additional 48 weeks.
Study NCT02169089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01714947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^14C]-alisertib
Description: \[\^14C\]-alisertib oral solution
Study NCT03222856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: MK3475 (pembrolizumab) will be supplied directly as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution.
Study NCT03222856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin will be supplied as a clear and colourless aqueous solution for injection provided in glass vials containing 2 ml. Each 2 ml vial contains eribulin mesylate equivalent to 0.88 mg eribulin.
Study NCT02368483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Description: Neuromuscular training for the hip and lower limb muscles.The training program is divided into 3 phases, and includes specific exercises for improving the hip range of motion, muscle strength of the hip and lower limb muscles, as well as the trunk stability and coordination. The intervention lasts 12 weeks. Patients will train 2 times/week with a physical therapist and 2 times/weeks alone at home.
Study NCT01719133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Histamine
Description: positive control
Study NCT01719133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AllerT1
Description: synthetic peptide T1
Study NCT01719133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AllerT2
Description: synthetic peptide T2
Study NCT01719133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AllerT3
Description: synthetic peptide T3
Study NCT01719133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AllerT4
Description: synthetic peptide T4
Study NCT01714947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Alisertib enteric coated tablets
Study NCT00677742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced initial supply of oral contraception
Description: 7 packs of pills, or 1 pack of pills and a prescription for 6 refills
Study NCT01719133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AllerT5
Description: synthetic peptide T5
Study NCT01719133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: mix of AllerT1-T2-T3
Description: mix of peptides T1, T2 and T3
Study NCT01719133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: mix of AllerT4-T5
Description: mix T4-T5
Study NCT02815592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986012
Study NCT02815592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT00677742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional initial supply of oral contraception
Description: 3 packs of pills, or 1 pack of pills and a prescription for 2 refills
Study NCT02815592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Study NCT02477215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
Study NCT02815592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02815592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum
Study NCT02815592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Study NCT02815592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01438450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral
Description: Capecitabine : 500 mg OD x 1 week 500 mg BD x 1 week 500 mg (2 morning, 1 evening) x 1 week After attaining the max dose of 1500 mg, a cycle of Capecitabine 1500mg every day for 2 weeks and 1 week off to be maintained.~Thalidomide: 50 mg OD x 1 week 100 mg OD x 1 week 200 mg OD x 1 week, 300 mg OD x 1 week
Study NCT01438450 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Supportive
Description: No specific therapy will be given
Study NCT01203072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b
Description: DU-176b 5mg tablets oral, once daily for 2 weeks
Study NCT01203072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b
Description: DU-176b 15mg tablets, oral once daily for 2 weeks
Study NCT01203072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b
Description: DU-176b 30 mg tablets, oral, once daily for 2 weeks
Study NCT01203072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b
Description: DU-176b 60 mg tablets, oral, once daily for 2 weeks
Study NCT01203072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral tablets, once daily for 2 weeks
Study NCT00235872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg eow, sc
Study NCT01450410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinic acid
Description: Nicotinic acid / laropiprant (Tredaptive 1000 mg/20 mg modified-release tablets). Patients treated with nicotinic acid 1g/day receive one dose of one month and 2 g / day thereafter. Nicotinic acid treatment will last for 12 weeks.
Study NCT01450410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment will last for 12 weeks.
Study NCT02972632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablet
Study NCT02032147 — intervention group
Intervention type: DRUG
Intervention: NGF group
Description: This group will be treated with NGF 18u per day im for 60 days
Study NCT04738110 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: Structural MR (T2, FLAIR, T1 and T1+C), DCE, DSC
Study NCT02477215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.
Study NCT02477215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine (multiple dose levels)
Description: 70 mg/m\^2, 80 mg/m\^2, or 90 mg/m\^2 on days 1 and 2
Study NCT02477215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine (MTD)
Description: 80 mg/m\^2 on days 1 and 2
Study NCT00960323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered alone in the morning on Day 1.
Study NCT00960323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin (1 x 40 mg tablet) administered once daily on Days 15-28.
Study NCT00960323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered with a single dose of 40 mg atorvastatin in the morning on Day 28 after an overnight fast.
Study NCT03534089 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard infant fomula
Description: Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula without lactoferrin supplementation.
Study NCT03534089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level LF infant formula
Description: Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula supplemented with low level of lactoferrin (38mg/100g).
Study NCT03534089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High level LF infant formula
Description: Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula middle supplemented with high level of lactoferrin (76mg/100g).
Study NCT02785588 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3.0 T Neonatal MRI scanner
Description: eligible subjects will undergo neonatal MRI scan procedure
Study NCT01332422 — intervention group
Intervention type: DRUG
Intervention: Salmeterol and Fluticasone
Description: Collection of safety data
Study NCT01990417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive stretching
Description: Passive stretching of the hamstrings was performed only once, lasting 30 seconds, and initiated on the right leg. Participants were in supine position with head, trunk and arms aligned along the body. The researcher remained ipsilateral to the subject´s leg being stretched and applied external force to the limit tolerated by the participant. The researcher performed a hip flexion, knee extension, and dorsiflexion of the ankle while the opposite leg remained extended on the ground.
Study NCT00995202 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Monitoring CEA
Description: No specific follow-up of CEA
Study NCT02220517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-guided in-bore prostate biopsy
Description: Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
Study NCT02220517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI/US fusion-guided prostate biopsy
Description: Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)
Study NCT03791463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salvianolic acid A
Description: Following an overnight fast of at least 10 hours, a single dose of 90 mg salvianolic acid A will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
Study NCT03075020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbon monoxide
Description: carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass
Study NCT04180072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg IV on day 1 every 3 weeks
Study NCT04180072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks
Study NCT02652455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants entering the study after the first 6 participants only: Treatment with nivolumab prior to removal of tumor sample for TIL growth. About 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.
Study NCT03075020 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AIR
Description: Room air will be administered as placebo
Study NCT00984724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Treatment (ST)
Description: Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).
Study NCT02652455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery to Remove Tumor for Growth of TIL
Description: All participants: Tumor sample taken for growth of TILs. Growing the TILs takes about 4-8 weeks.
Study NCT02652455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD137
Description: All participants: Anti-CD137 agonistic antibody as an agent to augment T cell proliferation in vitro. The growth of the TIL will be accelerated by the use of CD137 activating antibody in the laboratory.
Study NCT02652455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: All participants: Lymphodepleting chemotherapy intravenously, beginning 3 to 6 weeks after tumor collection for TIL growth.
Study NCT02652455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: All participants: Lymphodepleting chemotherapy intravenously, beginning after first 2 days of cyclophosphamide.
Study NCT02652455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL Infusion
Description: After completing one week of lymphodepleting chemotherapy, all participants will be admitted back into the hospital for IV infusion of the TIL cells.
Study NCT00984724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: MAPS-6: 6 MAPS proactive telephone counseling sessions delivered over a 2-year period~MAPS-12: 12 MAPS proactive telephone counseling sessions over a 2-year period
Study NCT00984724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline
Description: Letter referring participants to a Quitline providing quit smoking services.
Study NCT02652455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After TIL infusion, in-patient high dose IL-2 treatment.
Study NCT00739388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacytidine
Description: 100 mg/m2/day s.c. on days 1-5 of a 28-day cycle
Study NCT04043663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality glasses
Description: Children are encouraged to watch the virtual reality program at least 24 hours before surgery.
Study NCT00984724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: 300 pieces of nicotine gum issued at baseline visit.
Study NCT00995202 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intensive Monitoring CEA
Description: CEA levels are measured every 3 months for 3 years, then every 6 months for 2 years.
Study NCT00995202 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Monitoring Imagery
Description: Abdominal ultrasound examination every 3 months during 3 years then every 6 months during 2 years then annually. Chest X-ray examination eveyr 6 months during 3 years then annually during 2 years
Study NCT00995202 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intensive Monitoring Imagery
Description: Alternation every 3 months of TDM thoraco-abdomino-pelvis and abdominal ultrasound examination during 3 years and twice a year after during 2 years. Coloscopy at 3 years and then evry 5 years if normal
Study NCT01134458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Intervention
Description: 1. Health Dialog Cardiac Risk Calculator~2. Health Dialog's Living with Coronary Heart Disease~3. Tailored intervention including health behavior modules such as smoking cessation, exercise, diet, and weight
Study NCT04522349 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Greifer then Axon-Hook
Description: Each participant is fitted with a Greifer and assessed after two weeks home-trial. Then he is fitted with Axon-Hook and assessed after two weeks home trial.
Study NCT04043663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard perioperative care without virtual reality program
Description: standard perioperative care without virtual reality program
Study NCT02705456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Brushing HA
Description: 2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks).
Study NCT02705456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth Brushing FL
Description: 2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks).
Study NCT01678755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: ABT-126 Low Dose
Study NCT01678755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: ABT-126 High Dose
Study NCT01678755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02054000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirofiban
Description: Intracoronary administering of Tirofiban
Study NCT04522349 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Axon-Hook then Greifer
Description: Each participant is fitted with a Axon-Hook and assessed after two weeks home-trial. Then he is fitted with Greifer and assessed after two weeks home trial.